KLK3 and posterior cortical atrophy: DecipherTM has received approval in the United States for evaluating the likelihood of experiencing biochemical recurrence (BCR) or clinical progression (e.g., metastasis) in post-RP PCa patients with an adverse pathology (pT3 and/or positive margins or biochemical failure) or PSA persistence or recurrence during the follow-up period.